Annovis Bio Inc. (ANVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANVS Stock Price Chart Interactive Chart >
ANVS Price/Volume Stats
|Current price||$109.44||52-week high||$132.00|
|Prev. close||$112.24||52-week low||$4.14|
|Day high||$117.86||Avg. volume||795,644|
|50-day MA||$83.46||Dividend yield||N/A|
|200-day MA||$32.83||Market Cap||760.28M|
Annovis Bio Inc. (ANVS) Company Bio
Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
ANVS Latest News Stream
|Loading, please wait...|
ANVS Latest Social Stream
View Full ANVS Social Stream
Latest ANVS News From Around the Web
Below are the latest news stories about Annovis Bio Inc that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
Terminator3D/iStock via Getty Images Earlier this year, we wrote that Cassava Sciences (SAVA) could be the best performing stock of 2021. Cassava is up quite a bit since then, but we think it still has a very long way to go. Here are five reasons why. 1) No Disease-Modifying Therapies...
knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to major stock swings. This year's conference comes less than...
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.
New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28. A poster presentation featuring positive clinical outcome data from the Company's two Phase 2a studies will be available on Monday, July 26 Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, wi
Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022
Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's (NYSE: ANVS) Phase 2 Alzheimer's disease trial evaluating ANVS401. The DSMB has approved the study to proceed with Cohort 3, the final cohort of the study. Funding for this research was provided by a grant from the National Institutes on Aging. The study is run by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine. The safety e
ANVS Price Returns